- Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
- Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting
- Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
- Annexon Announces Pricing of $125 Million Underwritten Public Offering
- Annexon Announces Proposed Public Offering of Common Stock
- Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
- Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data
- Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
- Annexon Biosciences to Present at the Bank of America Health Care Conference
- Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting
More ▼
Key statistics
On Wednesday, Annexon Inc (ANNX:NSQ) closed at 4.80, 205.41% above the 52 week low of 1.57 set on Oct 16, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.66 |
---|---|
High | 4.91 |
Low | 4.62 |
Bid | 4.73 |
Offer | 4.80 |
Previous close | 4.57 |
Average volume | 2.43m |
---|---|
Shares outstanding | 103.48m |
Free float | 95.67m |
P/E (TTM) | -- |
Market cap | 472.40m USD |
EPS (TTM) | -1.46 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼